Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial.
Hematopoietic cell processing
Hematopoietic stem cell mobilization
Intermediate-dose cytarabine
Multiple myeloma
Stem cell transplantation
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
27
07
2018
accepted:
16
09
2018
pubmed:
30
9
2018
medline:
25
12
2019
entrez:
30
9
2018
Statut:
ppublish
Résumé
Mobilization of hematopoietic stem cells for patients with multiple myeloma (MM) may be done using either steady-state granulocyte colony-stimulating factor (G-CSF) or a combination of chemotherapy with G-CSF. The goal of this randomized, open-label, phase 3 trial was to compare the efficacy of chemomobilization using intermediate-dose cytarabine (ID-AraC) plus G-CSF with G-CSF alone in patients with MM referred for tandem autologous stem cell transplantation (autoSCT). The percentage of patients with stem cell yield of at least 5 × 10
Identifiants
pubmed: 30266677
pii: S1083-8791(18)30590-1
doi: 10.1016/j.bbmt.2018.09.023
pii:
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
248-255Informations de copyright
Copyright © 2018. Published by Elsevier Inc.